Evommune's oral EVO756 heads to a Phase 2b eczema readout in H2 2026
The 120-patient trial tests whether blocking MRGPRX2, a target with no approved drug in atopic dermatitis, can move EASI scores against placebo.
Executive Summary
- Evommune's Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis has finished enrolling and is now waiting on a top-line readout the company has guided to the second half of 2026.
- The trial is built to find an effective dose, not just prove a single binary win, by randomizing patients across multiple EVO756 dose levels against placebo and tracking eczema severity and itch.
- EVO756 targets a receptor that no approved or late-stage atopic dermatitis therapy blocks, so the readout functions as the first human efficacy test of this mechanism in the disease rather than a comparison against an established rival.
- The trial closed to enrollment at its original target with a stable amendment history, meaning execution risk is not the open issue; whether the dose-response data clear a clinically meaningful bar is.
The trial
NCT07150845 is a randomized, multicenter, double-blind, placebo-controlled, dose-ranging Phase 2b study of EVO756, an oral small-molecule antagonist of MRGPRX2, in adults with moderate-to-severe atopic dermatitis. The trial enrolled 120 patients across three EVO756 dose arms and a placebo arm, randomizing them to 12 weeks of treatment. The primary endpoint is percentage change in Eczema Area and Severity Index (EASI, a composite scale of eczema extent and severity) from baseline to week 12, with pruritus-NRS (an 11-point itch-severity scale) tracked as a key secondary measure. NCT07150845Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Why the mechanism matters
MRGPRX2 sits on mast cells and sensory neurons, the two cell types Evommune's own materials describe as central to the itch-scratch cycle that drives lesions in atopic dermatitis. Evommune's chief medical officer, Eugene Bauer, framed the rationale directly: "MRGPRX2 antagonism is exciting in its potential to change the paradigm as the first target that modulates both mast cells and sensory neurons". The company had already observed MRGPRX2 antagonism affecting mast cell activation in a Phase 2 chronic inducible urticaria trial before advancing EVO756 into atopic dermatitis. EvommuneEvommune Initiates Phase 2b Trial of its Oral MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Atopic DermatitisAug 27, 2025
The competitive frame
No other industry trial pairs the MRGPRX2 target with atopic dermatitis, and the nearest comparators in the field, JAK inhibitors such as upadacitinib and abrocitinib, and biologics such as dupilumab, work through entirely different mechanisms. The broader atopic dermatitis field remains active: AbbVie's upadacitinib alone runs three ongoing trials, and Sanofi's amlitelimab is in Phase 3 testing. Within MRGPRX2 specifically, only one other industry program, Arcus Biosciences' AB102, is in clinical testing, and that trial is a Phase 1 study not yet recruiting. That leaves EVO756 as the only Phase 2 asset testing MRGPRX2 antagonism in this indication, with no resolved same-target trial to benchmark against.
Operational status
The trial moved from Recruiting to Active, not recruiting on May 18, 2026, consistent with reaching its enrollment target at plan, and its enrollment held flat at 120 patients with no upward or downward revision. Its protocol-amendment history shows no changes to the primary completion date, endpoint definitions, or eligibility criteria since the trial opened, a pattern read as Stable. Evommune has repeated the same second-half-2026 guidance window across five disclosures dating back to the trial's August 2025 initiation, most recently narrowing it to the third quarter in a May 2026 business update. NCT07150845+1Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845Evommune Initiates Phase 2b Trial of its Oral MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Atopic DermatitisAug 27, 2025
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.